News

Panel backs approval of alirocumab, biologic injectable lipid-lowering drug

Publish date: June 9, 2015

 

AT AN FDA ADVISORY COMMITTEE MEETING

References

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Alogliptin CV risk acceptable, FDA panel agrees
MDedge Family Medicine
Testosterone therapy has neutral cardiovascular effects
MDedge Family Medicine
TRACE-RA: Statin therapy may prevent CVD in RA
MDedge Family Medicine
ILC: Statins linked to better outcomes in hepatitis C cirrhosis
MDedge Family Medicine
Biologics cut cholesterol, may reduce mortality
MDedge Family Medicine
Asymptomatic carotid stenosis and central sleep apnea linked
MDedge Family Medicine
Chest pain: Risks of evaluation may outweigh benefits
MDedge Family Medicine
AUA: Testosterone may not deserve its reputation as a cardiovascular culprit
MDedge Family Medicine
Traditional diagnostic criteria miss OSA in coronary artery disease patients
MDedge Family Medicine
FDA panel set to review two biologic lipid-lowering drugs for approval
MDedge Family Medicine

Related Articles